Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

5.7%

2 terminated out of 35 trials

Success Rate

91.7%

+5.2% vs benchmark

Late-Stage Pipeline

26%

9 trials in Phase 3/4

Results Transparency

18%

4 of 22 completed with results

Key Signals

4 with results92% success

Data Visualizations

Phase Distribution

14Total
Not Applicable (2)
P 1 (1)
P 2 (2)
P 3 (6)
P 4 (3)

Trial Status

Completed22
Enrolling By Invitation3
Active Not Recruiting3
Recruiting3
Unknown2
Terminated2

Trial Success Rate

91.7%

Benchmark: 86.5%

Based on 22 completed trials

Clinical Trials (35)

Showing 20 of 20 trials
NCT01500447RecruitingPrimary

Inherited Reproductive Disorders

NCT01851447Active Not RecruitingPrimary

Skeletal Muscle Biomarkers in People With Fragile Sarcolemmal Muscular Dystrophy

NCT04743466Active Not Recruiting

Evaluation of Association Between Testosterone Levels, Dementia, and Adverse Mental Health Outcomes

NCT05212428Not ApplicableActive Not RecruitingPrimary

DNA Sequencing in Clinical Practice, Mayo Clinic Health Tapestry Study

NCT02769949CompletedPrimary

Pediatric Patients With Metabolic or Other Genetic Disorders

NCT06144957Enrolling By Invitation

SLC13A5 Deficiency Natural History Study - United States Only

NCT05737602Not ApplicableEnrolling By Invitation

Promoting Stress Management and Resilience Among Individuals With Von Hippel- Lindau Disease

NCT06898307Recruiting

Utility of Gene Test Analysis for Diagnosis, Prognosis and Treatment of Patients With Genetic Arrhythmic Heart Disease: the ARRHYTHMIC GENE-HEART

NCT04681781Enrolling By Invitation

SLC13A5 Deficiency Natural History Study - Remote Only

NCT06362473Recruiting

Lipid Transport Disorder Italian Genetic Record (LIPIGEN)

NCT00705172CompletedPrimary

Retrospective Observational Study on Efficacy and Safety of Norditropin® in Children With Prader-Willi Syndrome

NCT01529944Phase 3CompletedPrimary

Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658

NCT03435627CompletedPrimary

Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome)

NCT00358657Phase 2Terminated

Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders

NCT01927861Phase 3CompletedPrimary

Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome

NCT03589079Unknown

Delineation of Novel Monogenic Disorders in the United Arab Emirates Population

NCT01517048Completed

Brain-Derived Neurotrophic Factor in Obesity and Brain Function

NCT00025870CompletedPrimary

Studies of Children With Metabolic and Other Genetic Disorders

NCT01135537Phase 2Terminated

Pharmacokinetics of Thymoglobulin in Paediatric Haematopoietic Stem-cell Transplants

NCT00960128Completed

Observational Prospective Study on Patients Treated With Norditropin®

Scroll to load more

Research Network

Activity Timeline